期刊文献+

托拉塞米治疗原发性高血压的临床评价 被引量:12

Efficacy and Safety of Torasemide in Patients with Mild to Moderate Essential Hypertension
暂未订购
导出
摘要 目的 评价托拉塞米 (torasemide)治疗轻、中度原发性高血压的疗效和安全性。方法 选择门诊轻、中度原发性高血压患者 (坐位舒张压 (DBP) 95mmHg~ 1 1 5mmHg) ,以随机、双盲、平行对照的方法 ,经 1~ 2周药物洗脱期后 ,随机分入托拉塞米组或吲哒帕胺缓释片剂 (indapamide)组 ,分别服用托拉塞米 5mg每日一次或吲哒帕胺缓释片剂2 5mg每日一次。治疗 4周末坐位DBP <90mmHg者结束试验 ;坐位DBP≥ 90mmHg者剂量分别加倍至托拉塞米1 0mg每日一次或吲哒帕胺缓释片剂 5mg每日一次 ,继续服用 4周。于洗脱期末及治疗 2、4、6、8周测量诊室血压、心率并记录症状、体征 ;治疗期前、治疗第 2周及试验结束时进行实验室检查。结果 共 1 30例合格的原发性高血压患者进入随机分组 ,1 1 8例完成试验 ,其中托拉塞米组 56例 (4周结束者 30例 ,8周结束者 2 6例 ) ,吲哒帕胺缓释片剂组 62例 (4周结束者 41例 ,8结束者周 2 1例 )。服药 4周后 ,总有效率托拉塞米组 67 86 % (38/ 56例 ) ,吲哒帕胺缓释片剂组 72 58% (45/ 62例 ) ;治疗 8周后 ,加量者总有效率托拉塞米组 34 62 % (9/ 2 6例 ) ,吲哒帕胺缓释片剂组61 90 % (1 3/ 2 1例 ) ,组间比较均无差异 (P =1 0 0 ,P =0 67)。两组药后 2、4、6、8周坐位舒张压的下降幅? Objective To evaluate the antihypertensive effect and safety of torasemide in Chinese patients with mild to moderate essential hypertension Methods After 1~2 weeks wash out, patients with mild to moderate essential hypertension(seated DBP 95~115 mmHg), were randomly assigned to received torasemide 5 mg or indapamide 2 5 mg once a day for 4 weeks, followed by a double dose for another 4 weeks in patients whose seated DBP were still ≥90 mmHg Blood pressure, heart rate, symptoms and signs were examined at the end of wash out and 2, 4, 6, 8 weeks Laboratory examinations were performed at baseline, 2 weeks and the end of the trial Results 130 essential hypertensive patients were recruited and randomized to receive either torasemide group ( n =64) or indapamide group ( n =66) 118 patients completed the trial, 56 patients in torasemide group(30 finished at the end of 4 weeks and 26 finished at the end of 8 weeks) and 62 in indapamide group(41 finished at the end of 4 weeks and 21 finished at the end of 8 weeks) At the end of 4 weeks, the effective rate was 67 86% in torasemide group and 72 58% in indapamide group At the end of 8 weeks, the effective rate in those whose dosage was doubled was 34 62% in torasemide group and 61 90% in indapamide group No statistical difference was found ( P =0 67) The decrease of seated DBP was of no differece between the two groups at the end of 2, 4, 6, 8 weeks The values of serum potassium, sodium, chloride were lower in indapamide group than those in torasemide group at 2 weeks and the end of the trial ( P <0 01 or P <0 05) Conclusion Torasemide 5 mg/d~10 mg/d is as effective as indapamide 2 5 mg/d~5 mg/d in patients with mild to moderate essential hypertension The impact of torasemide to serum electrolyte is much less than that of indapamide
出处 《高血压杂志》 CSCD 2003年第4期325-328,共4页 Chinese Journal of Hypertension
基金 国家"十五"重大科技专项课题 ( 2 0 0 2AA2Z34 11)
关键词 托拉塞米 吲哒帕胺 原发性高血压 torasemide indapamide essential hypertension
  • 相关文献

参考文献10

  • 1陈新谦 金有豫.新编药物学(第14版)[M].北京:人民卫生出版社,1997.487.
  • 2Cuvelier R, Pellegrin P, Lesen M, et al. Site of action of torasemide in man[J ]. Eur J Clin Phamacol, 1986,31 : 15 - 9.
  • 3Hermes H, Heridenreich O. Renal effects of torasemide in the ratclearance and micropuncture studies [ J ] . Arzneimittelforschung,1985,35:1532 - 5.
  • 4Neugebauer G, Besenfelder E, Von Moellendorff E. Pharma-cokinetica and metabolism of torasemide in man[ J ]. Arzneimittel forschung, 1988,38:161 - 6.
  • 5Barr WH, Smith HL, Karnes HT, et al. Comparison of bioavail-ability, pharmacokinetics and pharmacodynamics of torasemide in young and elderly healthy volunteers [ J ]. Prog Pharmacol Clin Pharmmol, 1990,8 : 15 - 28.
  • 6Spieker C, Zidek W, Hacker W, et al. Assessment of ontracellular sodium and calcitnn in essential hypertension during diuretic treatment[J]. Arzneimittel forschung, 1988,38:180 - 88.
  • 7Reyes AJ, Chiesa PD, Santucci MR, et al. Hydrochlorothiazide versus a non-diuretic dose of torasemide as once-daily antihypertensive monopharmacotherapy in elderly patients. A randomized and double-blind study[J]. Prog Pharmacol Clin Pharmmol,1990,8(1) :183-209.
  • 8Spannbrucker N, Achhammer I, Metz P, et al. Comparative study on the antihypertensive efficacy of torasemide and indapamide in patients with essential hypertension[J ]. Arzneimittelforschung, 1988,38 : 190 - 3.
  • 9Baumgart P, Walger P, von Eiff M, et al. Long-term efficacy and tolerance of torasemide in hypertension[J]. Prog Pharmacol Clin Pharmmol, 1990,8(1) : 169 - 81 .
  • 10Achhammer I, Eberhard R. Comparison of serum potassium levels during long- term treatment of hypertensive patients with 2.5 mg torasemide/day or 50 mg triamterene/25 mg hydrochlorothiazide/day[J]. Prog Pharmacol Clin Pharmmol, 1990,8(1) :211 - 20.

共引文献330

同被引文献40

引证文献12

二级引证文献27

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部